Omeros | OMER - Debt


Omeros reported $442.16M in Debt for its fiscal quarter ending in September of 2023.





Debt Change Date
Adma Biologics USD 83.12M 702K Sep/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Cytokinetics USD 1.29B 4.48M Mar/2026
Gilead Sciences USD 24.94B 5M Dec/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Immunic USD 0 0 Jun/2024
Insmed USD 727.62M 275K Mar/2026
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
Omeros USD 442.16M 199K Sep/2023
Pacira USD 367.66M 4.53M Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026
Xoma USD 120.79M 3.27M Jun/2024